Crossmark

Stereotactic body radiotherapy versus conventional/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer

Crossref DOI link: https://doi.org/10.1186/s13014-020-01658-5

Published Online: 2020-09-15

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Patel, Sagar A. http://orcid.org/0000-0001-5174-2096
Switchenko, Jeffrey M.

Fischer-Valuck, Ben

Zhang, Chao

Rose, Brent S.

Chen, Ronald C.

Jani, Ashesh B.

Royce, Trevor J.
License Information

Text and Data Mining valid from 2020-09-15

Version of Record valid from 2020-09-15
More Information

Article History

Received: 18 July 2020

Accepted: 31 August 2020

First Online: 15 September 2020

Ethics approval and consent to participate

: Institutional review board approval was waived for this de-identified, population-based database.

: Not applicable.

: Chen: Consulting or Advisory Role with Medivation/Astellas, Accuray, Bayer, Blue Earth Diagnostics. Research Funding with Accuray.Jani: Consulting or Advisory Role with Blue Earth Diagnostics.

Document is current

Any future updates will be listed below